Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QBQKB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
EBC-129
|
|||||
| Synonyms |
EBC-129
Click to Show/Hide
|
|||||
| Organization |
A*STAR (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti N256-glycosylated CEACAM5 and CEACAM6 antibody
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5); Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18/21 years (US/Singapore); weight 40-120kg; advanced/metastatic solid tumors refractory to standard therapy; ECOG PS ≤2 (Part A) or 0-1 (Parts B-D); adequate hepatic/renal/bone marrow function per protocol.
|
||||
| Administration Dosage |
EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and Day 1 of each 21- or 28-Day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05701527 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1A/B Study to Evaluate the Safety and Tolerability of EBC-129 As a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumours | ||||
| Primary Endpoint |
Primary endpoints include SAE/TEAE incidence (pre-screening to EOS), MTD/RP2D determination (Parts A/B/D), and ORR assessment (Parts C/D per RECIST v1.1) over 2 years.
|
||||
| Other Endpoint |
Secondary endpoints comprise efficacy measures (DCR, DoR, TTP, PFS, OS), PK parameters (Cmax, Ctrough, AUC, Tmax, t1/2 for EBC-129/pembrolizumab), immunogenicity (ADA/neutralizing antibodies), and tumor response comparisons (Part A) evaluated over 3.3 years.
|
||||